The discovery that activation of the MEK5/ERK5 route acted pathophysiologically in lung cancer in mice, together with the need to develop novel therapeutics for that disease, stimulated a study aimed at exploring the prognostic relevance of MEK5/ERK5 expression in that disorder, as well as the potential therapeutic value of its targeting. The gene discussed is MAP2K5; the disease is lung carcinoma.